Grotesque conflicts of interest on NIH ivermectin non-recommendation

Via Trial Site News

The National Institutes of Health provided a non-recommendation for the use of ivermectin in COVID-19, stating that there was:

“insufficient evidence … to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

The process for reaching that non-recommendation, however, is opaque. The Panel members responsible for therapy recommendations are disclosed and also that:

Continue reading “Grotesque conflicts of interest on NIH ivermectin non-recommendation”

Why All The Fuss About Ivermectin?

Authored by Brian C. Joondeph via AmericanThinker.com,

First hydroxychloroquine, now ivermectin, is the hated deadly drug de jour, castigated by the medical establishment and regulatory authorities. Both drugs have been around for a long time as FDA-approved prescription medications. Yet now we are told they are as deadly as arsenic.

As a physician, I am certainly aware of ivermectin but don’t recall ever writing a prescription for it in my 30+ years’ medical career. Ivermectin is an anthelmintic, meaning it cures parasitic infections. In my world of ophthalmology, it is used on occasion for rare parasitic or worm infections in the eye.

Ivermectin was FDA approved in 1998 under the brand name Stromectol, produced by pharmaceutical giant Merck, approved for several parasitic infections. The product label described it as having a “unique mode of action,” which “leads to an increase in the permeability of the cell membrane to chloride ions.” This suggests that ivermectin acts as an ionophore, making cell membranes permeable to ions that enter the cell for therapeutic effect.

Continue reading “Why All The Fuss About Ivermectin?”